As of November 2019 Emicizumab (Hemlibra®) has been made available for NHS Scotland Haemophilia centres to purchase for the treatment of severe Haemophilia A.
I had already been available for the treatment of people with an inhibitor by the decision at the end of last year made it available to a much wider group of people.
Emicizumab (Hemlibra®) is a new class of treatment for Haemophilia A. It isn’t factor replacement, instead it used a new molecule to play the roll of Factor VIII in the clotting process. The smaller molecule removes the need to infuse the treatment into a vein and replaces it with a weekly injection under the skin.
We’ve had a lot of questions from our members about the availability of Emicizumab (Hemlibra®) in Scotland so we asked National Services Division (NDS) for more details about the decision.
They told us,
Emicizumab (Hemlibra®) was added to the Risk Sharing Scheme for Inherited Haemostatic Disorders (IHD) Products in 2018 in the specific indication, “prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors”.
The license for the product was extended earlier this year to use in patients with “severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors. NHS Boards have agreed to include Emicizumab (Hemlibra®) in the IHD risk-share arrangements when used within the new indication.
Haemophilia centres in NHS Scotland will be contacting patients covered by the new indication to discuss the clinical benefits of them moving onto Emicizumab (Hemlibra®).
This treatment may not be appropriate for all patients and therefore each patient will require to be assessed to ensure that any change in their treatment is clinically appropriate and safe.
We understand that Scottish Centres will take a relatively cautious approach to rolling out the new treatment while they gain clinical experience of using the new therapy. However, there is no financial cap on the availability of the treatment in Scotland it’s take up will be on clinical grounds.
Anyone who is interested in finding out more about whether the new treatment would be appropriate for them should contact their Haemophilia Centre.